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Olfactory bulbectomyThe olfactory bulbectomy (OB) is an animal model of depression that results in behavioral, neurochemical
and neuroendocrinological changes, features comparable to those seen in depressive patients. This study in-
vestigated OB-induced alterations in locomotor activity and exploratory behavior in the open-ﬁeld test,
self-care and motivational behavior in the splash test, hyperactivity in the novel object test and novel cage
test, and the inﬂuence of chronic treatment with ﬂuoxetine (10 mg/kg, p.o., once daily for 14 days) on
these parameters. Fluoxetine reversed OB-induced hyperactivity in the open-ﬁeld test, locomotor hyperactiv-
ity and the increase in exploratory behavior induced by novelty in the novel object and novel cage tests, and
the loss of self-care and motivational behavior in the splash test. Moreover, OB decreased the number of
grooming and fecal boli in the open-ﬁeld and novel cage tests, alterations that were not reversed by ﬂuoxe-
tine. OB caused an increase in hippocampal, but not in prefrontal acetylcholinesterase (AChE) activity. Fluox-
etine was able to reverse the increase in hippocampal AChE activity induced by OB. Serum corticosterone was
increased in SHAM and bulbectomized mice treated with ﬂuoxetine. In conclusion, OB mice exhibited
depressive-like behaviors associated with an increase in hippocampal AChE activity, effects that were re-
versed by chronic treatment with ﬂuoxetine.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Animalmodels arewidely used tools to understand themechanisms
responsible for the etiology and treatment of various diseases, including
depression. The olfactory bulbectomy (OB) is an animal model of de-
pression characterized by the bilateral destruction of the olfactory
bulbs, which produces behavioral, neurochemical and neuroendocrino-
logical changes that resemble some of the symptoms observed in de-
pressed patients (Kelly et al., 1997; Leonard, 1984; Song and Leonard,
2005). OB causes several modiﬁcations in various brain regions, as con-
sequence of the disrupted connections between the bulbs and other
brain regions, mainly the olfactory–limbic circuitry (Jesberger and
Richardson, 1988; Kelly et al., 1997; Song and Leonard, 2005). The le-
sion caused by OB induces a reorganization process in limbic and corti-
cal areas and appears to be responsible for behavioral abnormalities
that appear 2 weeks after in rodents (Jarosik et al., 2007; Van Riezen
and Leonard, 1990; Zueger et al., 2005).
A hyperactivity response, themajor behavioral change in thismodel,
can be reversed by chronic treatment with antidepressants, mimicking, analysis of variance; HPA,
ulbectomy; 5-HT, serotonin;
: +55 48 3721 9672.
gmail.com (A.L.S. Rodrigues).
ier OA license.the slow onset of antidepressant action reported in clinical studies
(Kelly et al., 1997; Leonard and Tuite, 1981; Van Riezen and Leonard,
1990). Furthermore, OB leads to different signs of anhedonia as well
as cognitive deﬁcits (Harkin et al., 2003; Kelly et al., 1997; Song and
Leonard, 2005). Most of the studies evaluate only hyperactivity in
bulbectomized rodents (Harkin, et al., 2003; Kelly et al., 1997;
Leonard, 1984; Song and Leonard, 2005; Zueger et al., 2005). Further-
more, very few studies have analyzed self-care, motivational and/or an-
hedonic behavior associated with hyperactivity in bulbectomized rats
(Romeas et al., 2009).
OB has been suggested to possess a good face validity with human
depressive disorder, especially agitated depression (Harkin et al.,
2003; Kelly et al., 1997; Lumia et al., 1992; Romeas et al., 2009). An-
other important behavioral change triggered by OB is the increased
vulnerability and responsiveness to stress induced by novelty. These
behavioral deﬁcits may result from inappropriate and enhanced reac-
tivity to a novel environment (Leonard and Tuite, 1981; Song and
Leonard, 2005; Van Riezen and Leonard, 1990).
Moreover, OB in rodents has been associated with biochemical
changes, including alterations in brain levels of serotonin and noradrena-
line and the turnover of thesemonoamine neurotransmitters (Kelly et al.,
1997; Lumia et al., 1992; Song and Leonard, 2005), dysregulation of the
hypothalamic–pituitary–adrenal (HPA) axis with an increase in serum
corticosterone levels (Cairncross et al., 1977; Marcilhac et al., 1999), and
cholinergic dysfunction (Moriguchi et al., 2006; Nakajima et al., 2007).
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found in bulbectomized rodents are consistent with the well reported
hypofunction of serotonergic and noradrenergic systems and
dysregulation in the HPA axis, which is implicated in the pathophys-
iology of depression (Krishnan and Nestler, 2008; Nestler et al.,
2002). In addition, a higher activity of serum acetylcholinesterase
has been found in depressive patients (Tiwari et al., 1982). Although
cholinergic dysfunctions may account for the development of depres-
sion (Dagytė et al., 2011) and may be associated with behavioral
changes found in bulbectomized rodents, it is not clear whether ace-
tylcholinesterase activity is altered in brain structures closely impli-
cated with depression, such as the hippocampus and cerebral cortex
(Yamada et al., 2011).
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has
been widely used for the treatment of depression (Taylor and Stein,
2006; Wong et al., 2005). Moreover, several preclinical studies have
shown the antidepressant effect of ﬂuoxetine in predictive tests of an-
tidepressant activity as the forced swimming and tail suspension tests
(Brocardo et al., 2008; Cunha et al., 2008; Lobato et al., 2010; Machado
et al., 2009; Porsolt et al., 1979). Regarding OB, the effects of chronic
treatmentwith ﬂuoxetine seem to be controversial, with some studies
showing that this SSRI is not effective in reversing major behavioral
changes triggered by this model (Bellver et al., 1990) and others
showing that this antidepressant is able to reverse OB-induced hyper-
activity in the open-ﬁeld (Butler and Leonard, 1990; Roche et al.,
2007; Rodríguez-Gaztelumendi et al., 2009). Therefore, the ability of
ﬂuoxetine to reverse the main behavioral and biochemical alterations
in this model requires further investigation.
This study was aimed at investigating the effects of chronic ad-
ministration of ﬂuoxetine in three main behavioral changes induced
by OB in mice: hyperactivity in the open-ﬁeld test, hyperactivity in-
duced by novelty, and loss of motivational and self-care behavior,
which is postulated to reﬂect anhedonic behavior (Isingrini et al.,
2010; Moretti et al., 2012). In addition, the present study investigated
the effects of OB on serum corticosterone levels and acetylcholines-
terase (AChE) activity in the hippocampus and prefrontal cortex as
well as the ability of chronic ﬂuoxetine treatment to reverse possible
OB-induced alterations in these biochemical parameters.
2. Materials and methods
2.1. Animals
Female Swiss mice (50 to 55 days old, weighing 35–40 g) were
used for this study and maintained at constant room temperature
(21±1 °C) with free access to water and food, under a 12:12 h
light:dark cycle (lights on at 07:00 h). Mice were allowed to acclima-
tize to the holding room for 24 h before the behavioral procedure. All
experiments were carried out between 9:00 and 16:00 h. The proce-
dures in this study were performed in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory Animals
and approved by the Ethics Committee of the Institution. All efforts
were made to minimize animal suffering and to reduce the number
of animals used.
After 14 post-operative days (recovery period), mice were assigned
to one of the following groups: (I) SHAM-operated/distilled water
(SHAM/vehicle) as the control group; (II) SHAM-operated/
antidepressant treated mice (SHAM/ﬂuoxetine); (III) bulbectomized
mice treated with distilled water for 14 days (bulbectomized/vehicle);
(IV) bulbectomized mice treated with ﬂuoxetine for 14 days
(bulbectomized/ﬂuoxetine).
2.2. Drugs and treatment
Fluoxetine from Sigma Chemical Company, St. Louis, MO, U.S.A.
was used. Fluoxetine was dissolved in distilled water and givenonce a day by gavage (p.o.) over a period of 14 days (in a constant
volume of 10 ml/kg of body weight) at a dose of 10 mg/kg. The solu-
tions were freshly prepared each day. Controls received an identical
volume of distilled water (vehicle). The administration schedule and
the dose of the drug used were chosen on the basis of experiments
previously performed by us (Machado et al., 2007, 2009) as well as
other groups (Rodríguez-Gaztelumendi et al., 2009). Oral administra-
tion of ﬂuoxetine was chosen because it is the most common route of
administration in psychiatric patients.
2.3. Bilateral olfactory bulbectomy (OB) surgical procedure
After a 2-week acclimatization period, OB was performed
according to the procedure described by Leonard and Tuite (1981).
Brieﬂy, mice were anesthetized with xylazin (20 mg/kg, Virbac©,
Brazil) in combination with ketamine (100 mg/kg, Virbac©, Brazil),
diluted in saline (0.9% NaCl) and administered intraperitoneally
(i.p., 10 ml/kg body weight). The skull covering the olfactory bulbs
was exposed by skin incision and two burr holes were drilled using
a dentist drill. The olfactory bulbs were bilaterally aspirated using a
blunt hypodermic needle (1.0 to 1.2 cm long and with a rounded
tip of 0.80 to 1.2 mm of diameter) attached to a 10 ml syringe, taking
care not to cause damage to the frontal cortex. Finally, the burr hole
was ﬁlled with acrylic resin, in order to avoid bleeding and contami-
nation of the surgical site. SHAM-operations were performed in the
same way, but the olfactory bulbs were left intact. After surgery, all
animals were allowed to recover in a post-operative cage
(maintained at 24 °C) for 3 h. After this time period, mice were
returned to their home cage. The technique was adapted (Leonard,
1984; Leonard and Tuite, 1981; Van Riezen and Leonard, 1990;
Zueger et al., 2005) and standardized in our laboratory.
After behavioral testing (see Section 2.4), all animals were
sacriﬁced and the presence of lesion was veriﬁed. The bulbectomized
animals that showed incomplete removal of olfactory bulbs or dam-
age to other brain areas were excluded from subsequent analysis fol-
lowing the criteria previously described (Jarosik et al., 2007; Kelly
et al., 1997) (less than 15% of the total).
The 14 days post-surgery time interval was considered to be sufﬁ-
cient in order to guarantee an appropriate recovery of animals. Dur-
ing this period, development of persistent OB-induced effects, such
as increased locomotor activity and exploratory behavior were ob-
served (Jarosik et al., 2007; Van Riezen and Leonard, 1990; Zueger
et al., 2005).
As depicted in Fig. 1, 14 days after surgery (1st-14th day, recovery
period), drug treatment was started and continued for a period of
14 days (15th–28th day, treatment period).
2.4. Behavioral tests
One day before surgery, locomotor activity and exploratory behavior
were analyzed using the open-ﬁeld test. Behavioral changes after OB
and/or chronic treatment with ﬂuoxetine were examined by testing lo-
comotor activity and exploratory behavior in the open-ﬁeld 2 and
4 weeks after OB (2 weeks after the beginning of chronic ﬂuoxetine
treatment), as depicted in Fig. 1. All tests were carried out during the
light phase of the light/dark cycle. On the ﬁrst day of testing (day 29
of the experiment, 24 h after the last drug treatment), mice were sub-
mitted to the open-ﬁeld test. After 2 h, mice were submitted to the
splash test. On the second day of testing (day 30 of the experiment,
48 h after the last drug treatment), mice underwent the novel object
test. On day 31 (72 h after the last drug treatment), mice were submit-
ted to the novel cage test. Light intensity was approximately 200 lux.
2.4.1. Open-ﬁeld test
The open-ﬁeld test was used to investigate locomotor activity and
exploratory behavior, since locomotor hyperactivity is the key behavioral
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Fig. 1. Schematic representation of the experimental protocol indicating both the treatment period and the time of behavioral testing (OFT: open-ﬁeld test, splash test, NOT: novel
object test and NCT: novel cage test). Animals were sacriﬁced by decapitation 6 h after completion of behavioral testing on day 31, blood samples were collected and hippocampus
and prefrontal cortex were dissected and stored at −80 ° C for subsequent biochemical analysis.
222 D.G. Machado et al. / Pharmacology, Biochemistry and Behavior 103 (2012) 220–229feature of bulbectomized rodents. Mice were individually placed in a
wooden box (40×60×50 cm) with the ﬂoor divided into 12 squares.
Number of crossings (number of squares crossed by the animal using
all paws) was used to evaluate locomotor activity whereas number of
rearings (number of times the mice stood on its hind legs or engaged
in vertical exploratory activity) was used to assess exploratory behavior
(Machado et al., 2009; Van Riezen and Leonard, 1990; Zueger et al.,
2005). Additionally, the number of grooming episodes (washing of the
coat) and fecal boli was also determined (Kalueff and Tuohimaa, 2004;
Walsh and Cummins, 1976).
These parameters were assessed during a 6-min period. The appa-
ratus was cleaned with a solution of ethanol 10% between trials in
order to remove animal odors.
2.4.2. Splash test
The splash test was adapted from Yalcin et al. (2005). This test
evaluates grooming behavior, deﬁned as cleaning of the fur by licking
or scratching, after vaporization of 10% sucrose solution onto the
mouse's dorsal coat. The solution's viscosity prompts mice to initiate
grooming behavior, with depressive symptoms characterized by an
increased latency (idle time between spray and initiation of
grooming) and decreased time spent grooming (d'Audiffret et al.,
2010). Latency and time spent grooming were recorded for 5 min.
2.4.3. Novel object test
The novel object test was performed in the same arena and test
conditions employed for the open-ﬁeld test, in order to evaluate the
exploratory behavior of mice when exposed to an unknown object
(50 ml Falcon tube stylized with colorful stripes, placed top down).
In this experimental protocol, the novel object was placed in the cen-
ter of the open-ﬁeld (wooden box measuring 40×60×50 cm, with a
central area measuring 19.5×18.5 cm). The area that surrounds this
central part is referred to as the peripheral area. Latency to enter
the central area of the apparatus where the novel object was, time
spent exploring the novel object, and number of rearing episodes in
the central area were recorded during 6 min (adapted from Zueger
et al., 2005). The apparatus was cleaned with a solution of ethanol
10% between tests in order to remove animal odors.
2.4.4. Novel cage test
To investigate exploratory behavior in a novel environment, a cir-
cular blue plastic arena (d=44 cm, h=22 cm) with its ﬂoor divided
into 9 parts was used. Animals were placed in the center of this appa-
ratus at the beginning of the test. The number of crossings and rearing
episodes was recorded during 6 min (adapted protocol from Zueger
et al., 2005). Additionally, the number of grooming (washing of thecoat) episodes and fecal boli was also registered (Kalueff and
Tuohimaa, 2004; Walsh and Cummins, 1976).
After each test, the apparatuswas sprayedwith a solution of ethanol
10% and wiped thoroughly to clean and eliminate the residual odor.
2.5. Biochemical analysis
Blood collection was performed by decapitation 6 h after the last
behavioral test, as depicted in Fig. 1. Blood samples were collected
and allowed to coagulate at room temperature for 30 min and were
subsequently centrifuged at 3000g for 10 min. Serum was removed
and stored at −80 °C until analysis.
For AChE determination, hippocampus and prefrontal cortex were
dissected and homogenized in potassium phosphate buffer (0.1 M,
pH 8). The homogenates were centrifuged at 2300g for 15 min and
the supernatant was separated and stored at −80 °C until analysis.
2.5.1. Serum corticosterone determination
Serum corticosterone concentration was assessed with a commer-
cially available ELISA kit according to the manufacturer's instructions
(Assay Designs Inc., Ann Arbor, MI).
2.5.2. Determination of AChE activity
AChE activity was measured by the method described by Ellman
et al. (1961), using acetylthiocholine iodide as a substrate in
homogenates of hippocampus and prefrontal cortex. Each sample
was assayed in triplicate. The rate of hydrolysis of acetylthiocholine
iodide was measured at 412 nm through the release of the thiol com-
pound, which reacts with 5,5′-dithiobis-(2-nitrobenzoic acid (DTNB)
producing the colored product thionitrobenzoic acid.
2.5.3. Protein determination
Protein content in hippocampal and prefrontal cortex homogenate
samples was quantiﬁed using the method of Bradford (1976), using
bovine serum albumin as a standard.
2.6. Statistical analysis
Comparisons between pre-operative and post-operative periods
(SHAM×OB groups) were performed by repeated one-way measures
analysis of variance (ANOVA). Two-way ANOVA was used to assess
signiﬁcance of the post-treatment period (SHAM×OB–vehicle treat-
ment and SHAM×OB–ﬂuoxetine treatment groups), followed by
Duncan's multiple range post-hoc test when appropriate. All data
are expressed as means±standard error of the mean (S.E.M.). Differ-
ences with Pb0.05 were considered statistically signiﬁcant.
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Fig. 2. Effect of OB on the number of crossings (panel A) and rearing episodes (panel B) in the open-ﬁeld test during both pre-operative and post-operative (2 weeks after OB)
periods. Each column represents the mean+S.E.M. of 9–11 animals. **Pb0.01 as compared to control group (SHAM); ++Pb0.01 as compared with pre-operative period. Results
were analyzed by repeated measures ANOVA, followed by Duncan's multiple range post-hoc test.
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3.1. OB-induced locomotor and exploratory behavior in the
open-ﬁeld test
Two weeks after the OB procedure, bulbectomized mice showed
increased number of crossings and rearing episodes in the
open-ﬁeld test (Fig. 2A and B, respectively) when compared with
the pre-operative period, which indicates an increase in locomotor
and exploratory behaviors with OB. Moreover, locomotor and explor-
atory activities of bulbectomized mice were higher than those ob-
served in the SHAM-group. A repeated measures ANOVA revealed
a signiﬁcant effect of OB [F(1,38)=35.39, Pb0.01] and time0
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Fig. 3. Effects of chronic ﬂuoxetine treatment (10 mg/kg, p.o. during 14 days) of bulbectom
episodes (panel C) and fecal boli (panel D) as assessed by the open-ﬁeld test. Each column r
group (SHAM–vehicle); +Pb0.05, ++Pb0.01 as compared with OB–vehicle group. Results w[F(1,38)=34.09, Pb0.01] in locomotor activity and exploratory be-
havior, respectively, when compared to SHAM-operated controls.
3.2. Effect of chronic treatment with ﬂuoxetine on OB-induced locomotor
and exploratory hyperactivity in the open-ﬁeld test
The results depicted in Fig. 3A and B show that bulbectomized mice
presented an increase in the number of crossings and rearing episodes
in the open-ﬁeld test as compared to control mice (SHAM–vehicle), in-
dicating an OB-induced enhancement of locomotor and exploratory ac-
tivities. However, chronic treatmentwith ﬂuoxetinewas able to reverse
these parameters. A two-way ANOVA revealed a signiﬁcant main effect
of OB [F(1,36)=13.14, Pb0.01] as well as a signiﬁcant treatment×OB0
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Fig. 4. Effect of chronic ﬂuoxetine treatment (10 mg/kg, p.o. during 14 days) of
bulbectomized mice on the exploratory activity as assessed with the novel object
test. Exploratory behavior was assessed by monitoring the latency to enter the central
arena of the apparatus (area where the novel object was located; panel A), time spent
exploring the novel object (panel B) and number of rearing episodes in the central area
of the open-ﬁeld (panel C). Each column represents the mean+S.E.M. of 8–11 animals.
**Pb0.01 compared with the control group (SHAM–vehicle) and ++Pb0.01 as com-
pared with OB–vehicle group. Results were analyzed with a two-way ANOVA, followed
by Duncan's multiple range post-hoc test.
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ment [F(1,36)=0.71, P=0.40] in locomotor activity in the open-ﬁeld
test. Furthermore, statistical analysis also revealed a signiﬁcant effect
of OB [F(1,36)=11.37, Pb0.01], and a signiﬁcant treatment×OB inter-
action [F(1,36)=16.24, Pb0.01], but no signiﬁcant effect of treatment
[F(1,36)=0.21, P=0.64] in exploratory activity (rearing episodes).
Additionally, bulbectomized mice presented a decrease in the
number of grooming episodes and fecal boli as compared to the con-
trol group (SHAM–vehicle) (Fig. 3C and D, respectively). Fluoxetine
did not reverse OB-induced alterations in these parameters. A
two-way ANOVA revealed a signiﬁcant main effect of OB [F(1,36)=
10.55, Pb0.01], but no signiﬁcant effect of treatment [F(1,36)=2.37,
P=0.13] nor a signiﬁcant treatment×OB interaction [F(1,36)=0.25,
P=0.61] in the number of grooming episodes. A two-way ANOVA
also revealed a signiﬁcant effect of OB [F(1,36)=14.81, Pb0.01], but
no signiﬁcant effect of treatment [F(1,36)=0.52, P=0.47] nor a sig-
niﬁcant treatment×OB interaction [F(1,36)=3.56, P=0.067] in the
number of fecal boli.
3.3. Effect of chronic treatment with ﬂuoxetine on OB-induced
hyperactivity induced by novelty in the novel object test
Fig. 4 shows that OB caused a signiﬁcant decrease in the latency to
enter the central area of the apparatus (where the novel object was lo-
cated), an increase in the time spent exploring the novel object, and an
increase in the number of rearings in the central area of the apparatus as
compared to the control group (SHAM–vehicle) (Fig. 4A, B, C, respec-
tively). These results indicate an OB-induced hyperactivity in the
novel object test. Furthermore, chronic treatment with ﬂuoxetine in
bulbectomized mice abolished novelty-induced hyperactivity, since it
decreased the time spent exploring the novel object and the number
of rearings in the central area (Fig. 4B and C). However, ﬂuoxetine did
not alter the OB-induced reduction in the latency to enter the central
area of the apparatus (Fig. 4A). A two-wayANOVA revealed a signiﬁcant
main effect of OB [F(1,37)=22.01, Pb0.01], but no signiﬁcant effect of
treatment [F(1,37)=0.36, P=0.55] nor a signiﬁcant treatment×OB in-
teraction [F(1,37)=0.69, P=0.41] in the latency to enter the central
area. Moreover, a signiﬁcant main effect of OB [F(1,37)=12.79,
Pb0.01] and a signiﬁcant treatment×OB interaction [F(1,37)=7.35,
Pb0.01], but no signiﬁcant main effect of treatment [F(1,37)=3.29,
P=0.08] were observed in the time of exploration of the novel object.
Regarding the number of rearing episodes, a signiﬁcant main effect of
OB [F(1,37)=9.62, Pb0.01] and treatment [F(1,37)=5.93, Pb0.05] as
well as a signiﬁcant treatment×OB interaction [F(1,37)=7.70,
Pb0.01] was observed.
3.4. Effect of chronic ﬂuoxetine treatment on novelty-induced hyperactivity
in bulbectomized mice in the novel cage test
As shown in Fig. 5, bulbectomized mice showed locomotor and ex-
ploratory hyperactivity induced by a novel environment when com-
pared to SHAM–vehicle mice in the novel cage test (Fig. 5A and B,
respectively). However, bulbectomized mice that were submitted to
chronic treatment with ﬂuoxetine demonstrated a signiﬁcant decrease
in locomotor activity and exploratory behavior as compared to OB–
vehicle mice. A two-way ANOVA revealed a signiﬁcant effect of OB
[F(1,37)=12.98, Pb0.01], a signiﬁcant treatment×OB interaction
[F(1,37)=10.76, Pb0.01], but no signiﬁcant main effect of treatment
[F(1,37)=0.073, P=0.78] in locomotor activity. A two-way ANOVA
also revealed a signiﬁcant main effect of OB [F(1,37)=17.54, Pb0.01],
a signiﬁcant treatment×OB interaction [F (1,37)=8.94, Pb0.01], but
no signiﬁcantmain effect of treatment [F(1,37)=0.035, P=0.85] in ex-
ploratory activity.
Bulbectomized mice also showed a decreased number of grooming
episodes and fecal boli as compared to their controls (SHAM–vehicle)
(Fig. 5C and D, respectively) in the novel cage test. Bulbectomizedmice submitted to chronic treatment with ﬂuoxetine did not demon-
strate signiﬁcant alterations in these parameters, as compared to the
OB–vehicle (animals submitted to surgery and treatmentwith vehicle).
However, mice from the SHAM-group thatwere treatedwithﬂuoxetine
presented a decrease in the number of grooming episodes, but no signif-
icant differences in the number of fecal boli, as compared to their con-
trols (SHAM–vehicle). A two-way ANOVA revealed a signiﬁcant main
effect of OB [F(1,37)=6.84, Pb0.05] and treatment [F(1,37)=6.35,
Pb0.05], as well as a signiﬁcant treatment×OB interaction [F(1,37)=
4.30, Pb0.05] in the number of grooming episodes. A two-way ANOVA
also revealed a signiﬁcant effect of OB [F(1,37)=18.73, Pb0.01], but
no signiﬁcant effect of treatment [F(1,37)=0.27, P=0.60] nor a signif-
icant treatment×OB interaction [F(1,37)=1.11, P=0.29] in the num-
ber of fecal boli.
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depressive-like behavior as assessed by the splash test
The effects of chronic ﬂuoxetine treatment in the loss of self-care
and motivational behavior induced by OB were inferred by the latency
and time spent grooming in the splash test, as shown in Fig. 6A and B,
respectively. The results show an increased latency (idle time between
spray and initiation of grooming) and decreased time spent grooming in
bulbectomized mice. Noteworthy, chronic treatment with ﬂuoxetine0
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teraction [F(1,35)=4.31, Pb0.05], but no signiﬁcant main effect of
treatment [F(1,35)=1.54, P=0.22] in the latency to exhibit grooming
behavior in the splash test. A two-way ANOVA also revealed a signiﬁ-
cant main effect of OB [F(1,35)=7.55, Pb0.01] and treatment
[F(1,35)=17.68, Pb0.01] as well as a signiﬁcant treatment×OB inter-
action [F(1,35)=10.02, Pb0.01] in the time spent grooming.0
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levels in bulbectomized mice
Fig. 7 shows that chronic administration of ﬂuoxetine increased
serum corticosterone levels in both SHAM and OB groups as compared
with their respective control groups (SHAM–vehicle and OB–vehicle,
respectively). Additionally, serum corticosterone levels were not signif-
icantly increased in bulbectomized mice, although a 2.5 fold increase
was observed in the OB mice as compared with their controls
(SHAM–vehicle). A two-way ANOVA revealed a signiﬁcant main effect
of OB [F(1,31)=10.27, Pb0.01] and treatment [F(1,31)=101.54,
Pb0.01], but no signiﬁcant treatment×OB interaction [F(1,31)=1.83,
P=0.18].
3.7. Effect of chronic treatment with ﬂuoxetine on AChE activity in
bulbectomized mice
Fig. 8 shows the effect of chronic administration of ﬂuoxetine on
the activity of the enzyme AChE in the prefrontal cortex (Fig. 8A)
and hippocampus (Fig. 8B) of bulbectomized mice. As demonstrated
in Fig. 8A, the activity of AChE in the prefrontal cortex was reduced
in bulbectomized mice treated with ﬂuoxetine (10 mg/kg, p.o.) as
compared with OB vehicle-treated mice. A two-way ANOVA revealed0
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Fig. 8. Effect of chronic ﬂuoxetine treatment (10 mg/kg, p.o. during 14 days) of bulbectom
expressed as nmol/min/mg protein. Each column represents the mean+S.E.M. of 7–8 a
++Pb0.01 as compared with OB–vehicle group. Results were analyzed by a two-way ANOVa signiﬁcant treatment×OB interaction [F(1,25)=7.28, Pb0.05], but
not of OB [F(1,25)=1.38, P=0.25] and a signiﬁcant main effect of
treatment [F(1,25)=1.13, P=0.30] on the activity of AChE in the pre-
frontal cortex. However, Fig. 8B shows a signiﬁcant increase in the ac-
tivity of this enzyme in the hippocampus of bulbectomized mice, an
effect that was reversed by ﬂuoxetine treatment. Accordingly, a
two-way ANOVA revealed a signiﬁcant main effects of OB
[F(1,25)=4.82, Pb0.05] and treatment [F(1,25)=6.92, Pb0.05] as
well as a signiﬁcant treatment×OB interaction [F(1,25)=4.32,
Pb0.05] in AChE activity in the hippocampus.
4. Discussion
The removal of olfactory bulbs in rodents results in several behav-
ioral, neurochemical, and neuroendocrinological alterations, compa-
rable to those seen in patients with major depression (Kelly et al.,
1997; Song and Leonard, 2005). The present study sought to investi-
gate the ability of chronic treatment with ﬂuoxetine in reversing the
OB-induced behavioral (mainly hyperactivity and loss of self-care
and motivational behavior) and biochemical (serum corticosterone
and AChE activity in the hippocampus and prefrontal cortex)
alterations.
Previous studies have mainly used male rats to study changes in-
duced by OB and only a few have investigated hyperactivity and an-
hedonic behavior in female mice. Notably however, depression is
more prevalent in women than men—the female:male ratio can be
as high as 5:2 (Wong and Licinio, 2001).
A distinguishing feature of OB is its association with both hyperac-
tivity and anhedonic behavior. Thus, this model mimics the symp-
toms of depression associated with psychomotor agitation (Romeas
et al., 2009). Our results are in accordance with literature, since it
was previously reported that bulbectomized mice display a signiﬁ-
cant increase in locomotor and exploratory activities in the
open-ﬁeld test, which is indicative of a depressive-like behavior
(Harkin et al., 2003; Kelly et al., 1997; Zueger et al., 2005). Notewor-
thy, the open-ﬁeld test was performed under high luminance, which
was previously shown to be necessary for bulbectomized animals to
present hyperactivity (Mar et al., 2002).
The effects of SSRI antidepressants have received considerable
attention in the context of the OB model, since OB was reported to
cause a hyposerotonergic depressive-like phenotype (Kelly et al., 1997;
Lumia et al., 1992; Song and Leonard, 2005). However, the ability of
chronic treatment with ﬂuoxetine to reverse hyperlocomotion in
bulbectomized rodents is controversial (Bellver et al., 1990; Butler
and Leonard, 1990; Mar et al., 2002; Possidente et al., 1996;
Rodríguez-Gaztelumendi et al., 2009). In the present study,0
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mice during a 14 day period was able tomitigate the alterations in loco-
motor activity and exploratory behavior triggered by OB. These observa-
tions are in agreement with previous studies performed in male rats
(Butler and Leonard, 1990; Mar et al., 2002; Rodríguez-Gaztelumendi
et al., 2009), which validates the use of female mice.
Although the estrous cycle has not been evaluated in the present
study, a recent work demonstrated that OB could modify the estrous
cycle, reducing both the length and number of cycles (Carlini et al.,
2012). However, it was demonstrated that the behavioral effects of
OB in the open-ﬁeld and in the elevated plus-maze are not inﬂuenced
by sexual hormones (Stock et al., 2001). Noteworthy, anhedonic be-
havior is more observed in bulbectomized females than male rodents
as reported by Stock et al. (2000) which showed that OB-females
(both intact and ovariectomized) exhibited signiﬁcantly lower su-
crose preference levels than OB-males (both intact and gonadecto-
mized) and control animals.
In our investigation, bulbectomized mice showed locomotor hy-
peractivity and an increased novelty-induced exploratory behavior,
as assessed with the novel object and novel cage tests. These results
are consistent with previous literature, showing that hyperactivity in-
duced by OB is associated with a greater response to novel environ-
ments and a deﬁcit in habituation to new situations (Mar et al.,
2000, 2002; Van Riezen and Leonard, 1990; Zueger et al., 2005).
This ﬁnding is similar to the one reported by Zueger et al. (2005),
who demonstrated an increased exploratory behavior with these
same tests in bulbectomized mice. These authors also showed a de-
crease in exploration in the center of the open-ﬁeld in bulbectomized
mice (anxious-like behavior) before prior to placing the object in the
center of the apparatus. In our study, we did not assess the time mice
spent exploring the center of the open-ﬁeld before introduction of the
novel object, making comparisons with the study by Zueger et al.
(2005) difﬁcult. However, the observed increased activity in the
novel cage and increased interaction with the novel object might in-
dicate an anxiolytic effect. This hypothesis is apparently reinforced
by the OB-induced decrease in grooming episodes and number of
fecal boli in both the open-ﬁeld and the novel cage tests. However,
it is important to note that an enhanced locomotor activity observed
in tests of exploratory behavior, although traditionally thought to
represent an anxiolytic effect, could also result from an increase in be-
havioral disinhibition and/or in impulsive behavior (Scearce-Levie
et al., 1999; Winstanley et al., 2004).
Chronic treatment with ﬂuoxetine (10 mg/kg, p.o.) was able to re-
verse the OB-induced locomotor hyperactivity, increased exploratory
behavior, and the novelty-induced increase in number of crossings
and rearing episodes in the novel object and novel cage tests. These
results are in accordance with previous studies indicating that chron-
ic treatment with antidepressants including ﬂuoxetine (10 mg/kg,
i.p., 21 days) is effective in restoring normal behavior by permitting
a more effective adaptation to novel stimuli. In particular, these anti-
depressants were shown to increase habituation to novelty in
bulbectomized animals, without altering this parameter in SHAM
control mice (Mar et al., 2000, 2002). Interestingly, in our study ﬂuox-
etine treatment was unable to alter the OB-induced decrease in the
latency to enter the central arena where the novel object was located.
We can speculate that this behavioral measure is not directly associ-
ated with the manifestation of depressive-like behavior, rather
representing an impulsive-like behavior related to the initial re-
sponse to the apparatus. This hypothesis is somewhat in agreement
with that previously proposed by Mar et al. (2002), suggesting that
ﬂuoxetine increases the rate of habituation in bulbectomized rats. It
remains to be established whether other antidepressant agents
would be able to alter this parameter.
Anhedonia, or hyposensitivity to pleasure, is one of the key symp-
toms of depression. This behavior can be inferred through a reduction
in sucrose intake or decreased time spent grooming evoked byspraying a solution of sucrose onto the back of animals (Jancsar and
Leonard, 1981; Song and Leonard, 2005; Yalcin et al., 2005). Previous
studies have mainly assessed the total time spent grooming or the
frequency of grooming as parameters to infer anhedonic behavior in
the splash test (David et al., 2009; Detanico et al., 2009; Moretti
et al., 2012, Yalcin et al., 2008). However, in our study we also
assessed the latency to initiate grooming as an additional parameter
(d'Audiffret et al., 2010). Our study shows that OB produced a loss
of self-care and motivational behavior in the splash test, since
bulbectomized mice took longer to initiate grooming and demon-
strated a decrease in grooming response when compared with con-
trol mice (SHAM). This result is somewhat in agreement with a
previous study showing a blunted response to the rewarding proper-
ties of amphetamine and a reduction in sucrose intake in
bulbectomized rats, again suggesting that OB can induce anhedonia
(Romeas et al., 2009; Stock et al., 2000). Interestingly, in our study,
ﬂuoxetine was able to reverse these behavioral alterations, indicating
that OB is a suitable model to investigate the effects of compounds
endowed with antidepressant/anti-anhedonic-like properties.
A dysfunction of serotonergic and cholinergic systems (Hellweg
et al., 2007; Lumia et al., 1992), as well as of the HPA axis (Krishnan
and Nestler, 2008; Nakajima et al., 2007; Nestler et al., 2002), has
been previously reported in bulbectomized rodents. As such, in this
study we also analyzed serum corticosterone levels and the activity
of the enzyme AChE both in the hippocampus and prefrontal cortex
of bulbectomized mice.
The concentration of corticosterone circulating in the serum was
used as an indicator of activation of the HPA axis. We found that
serum corticosterone levels were unaltered in bulbectomized mice, al-
though a non-signiﬁcant 2.5 fold increase was observed in animals sub-
mitted to OB as compared to their SHAM controls. Indeed, either an
increase (Cairncross et al., 1977; Marcilhac et al., 1999) or no changes
(Broekkamp et al., 1986; Van Hoomissen et al., 2011) in serum
or plasma corticosterone levels have been previously reported in
bulbectomized rodents. The exact role that cortisol levels play in
human depression is unclear, since HPA axis activation is neither neces-
sary nor sufﬁcient to induce depression andmanyhypercortisolemic in-
dividuals are not depressed while many depressed individuals are not
hypercortisolemic (Wolkowitz et al., 2009). In line with this idea,
hypocortisolemia was reported to be more frequent in atypical depres-
sion,which is characterized by symptomsof hypoarousal, hypersomnia,
hyperphagia, lethargy, pain, fatigue, and relative apathy, whereas
hypercortisolemia is commonly observed in melancholic depression,
in which hyperarousal, anxiety, insomnia, and loss of appetite are com-
monly found (Gold and Chrousos, 2002; Wolkowitz et al., 2009).
Interestingly, chronic administration of ﬂuoxetine increased
serum corticosterone levels both in SHAM and OB groups. These re-
sults are somewhat in agreement with those reported by Weber
et al. (2006) showing an increase in plasma and brain corticosterone
concentrations following acute and chronic (14 days) administration
of ﬂuoxetine (10 mg/kg, p.o.) in mice. Moreover, ﬂuoxetine was
also shown to induce an increase in serum corticosterone levels fol-
lowing acute administration (Serra et al., 2001), an effect that was
associated with the activation of the HPA axis, since this effect was
blocked by the glucocorticoid dexamethasone (Duncan et al., 1998).
Fluoxetine was also able to increase the levels of neuroactive
steroids including allopregnanolone, pregnenolone, progesterone,
and deoxycorticosterone in plasma and serum, as well as in the hip-
pocampus and cerebral cortex, probably through an enhancement of
the activity of neurosteroidogenic enzymes (Marx et al., 2006; Serra
et al., 2001; Uzunova et al., 2004). Overall, we can speculate
that the antidepressant-like effect of ﬂuoxetine observed in
bulbectomized mice does not result from a decrease in serum cortico-
sterone levels.
The OB procedure produces changes in several brain regions as a
consequence of the disrupted connections between the bulbs and
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campus and cerebral cortex (Kelly et al., 1997; Wrynn et al., 2000).
A dysfunction of certain brain areas of the limbic system has been im-
plicated in depression and antidepressant action (Drevets et al., 2008;
Krishnan and Nestler, 2008). Furthermore, previous studies reported
that the neurochemical and behavioral alterations induced by OB
are in part due to neurodegeneration of speciﬁc brain structures,
such as the hippocampus and frontal cortex (Jarosik et al., 2007;
Kelly et al., 1997; Wrynn et al., 2000). In accordance with this evi-
dence, a large body of post-mortem and neuroimaging studies of de-
pressed patients has reported reductions in gray-matter volume and
glial density in the prefrontal cortex and hippocampus, regions
thought to mediate the cognitive aspects of depression (Krishnan
and Nestler, 2008). Given this background and the well known in-
volvement of the cholinergic system in behavioral alterations elicited
by OB (Moriguchi et al., 2006; Nakajima et al., 2007) as well as in the
pathophysiology of depression (Dagytė et al., 2011), in the present
study we also measured AChE activity both in the hippocampus and
prefrontal cortex. AChE is an important constituent of cholinergic
neurotransmission that catalyzes the hydrolysis of acetylcholine in
the synaptic cleft, thus terminating its action. In the present study
we observed an increased activity of AChE in the hippocampus, but
not in the prefrontal cortex of bulbectomized mice, an effect that
was reversed by ﬂuoxetine. This ﬁnding suggests that an increased
hippocampal activity of this enzyme, with a consequent reduction
in acetylcholine levels, may be related to the depressive-like behavior
observed in bulbectomized animals. In line with this, the SSRI
citalopram was previously shown to cause acetylcholine release in
the hippocampus (Dagytė et al., 2011; Egashira et al., 2006). Also,
the administration of ZSET1446, which acts directly on the release
of acetylcholine, causes a reduction in depressive-like behaviors in
bulbectomized mice (Shioda et al., 2010). Therefore, this hippocam-
pus speciﬁc effect may be related with the abundant cholinergic in-
nervations received by this structure. However, it is important to
take into account that AChE activity in other limbic structures not
measured in the present study may be affected by the OB procedure.
Noteworthy, in our study, ﬂuoxetine was able not only to reverse
the OB-induced increase in hippocampal AChE, but also to reduce
AChE activity in the prefrontal cortex of bulbectomized mice, corrob-
orating the notion that this SSRI modulates cholinergic neurotrans-
mission (Dagytė et al., 2011). Accordingly, treatment with
ﬂuoxetine was shown to decrease the activity of AChE in human
serum and erythrocyte membranes (Müller et al., 2002). Moreover,
it is worth mentioning that donepezil, a classical AChE inhibitor,
was able to reduce cerebrocortical AChE in bulbectomized mice
(Yamada et al., 2011), a result similar to that shown in the present
study with ﬂuoxetine.
It is possible that the ability of ﬂuoxetine to reduce AChE activity and
consequently increase acetylcholine levels may result in a desensitiza-
tion of nicotinic acetylcholine receptors. In line with this, it has been
proposed that a ﬁne balance between activation and desensitization of
nicotinic receptors is required to yield relevant antidepressant-like ef-
fects (Mineur and Picciotto, 2010). Overall, our results are consistent
with the notion of an interaction between serotonergic and cholinergic
neurotransmission being involved in the antidepressant effect of
ﬂuoxetine.
In conclusion, our study has extended the behavioral characteriza-
tion of the OB model in mice. In particular, we have shown that OB
mice exhibited hyperactivity as well as loss of self-care and motiva-
tional behavior that may reﬂect an anhedonic-like behavior associat-
ed with an increased hippocampal AChE activity, parameters that
were reversed by chronic treatment with ﬂuoxetine. These ﬁndings
strongly indicate that this model is an effective tool for the study of
agitated depression associated with anhedonia and provides insight
on the use of ﬂuoxetine as a viable treatment for this sub-type of
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